Breaking News, Financial News

Financial Report: Hospira

Hospira

2Q Revenues: $869.4 million (+29.5)

2Q Earnings: $30.7 million (-43%)

YTD Revenues: $1.7 billion (+24%)

YTD Earnings: $1.3 million (-99%)

Comments: Pharmaceutical contract manufacturing revenues were $36.9 million in the quarter, down 26%, and $78 million YTD, down 23%. 2Q and YTD results include Mayne Pharma integration charges, and charges related to Hospira’s manufacturing initiatives. R&D expenses were $52.5 million, up 35% in the quarter and $96 million YTD, up 37%, impacted by acquired in-process R&D related to the acquisition of Mayne Pharma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters